All In Biotech

Drug Trial Radar · NCT02222545

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies

Last checked: Nov 20, 2026Latest source record: Aug 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

58

Actual

Start

Nov 2, 2014

Primary completion

Jan 30, 2020

Study completion Aug 11, 2020

Sponsor

Lead sponsor
Omeros CorporationIndustry
Sponsor type
Industry
First posted
Aug 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic microangiopathies (TMA).

Conditions

  • Thrombotic Microangiopathies

Interventions

  • OMS721Biological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMATime frame: Day 1 to 37 days after end of treatment, approximately up to 31 weeks.
  2. Number of Participants With HSCT-TMA Who Respond to OMS721Time frame: Day 1 to up to 2 years following the first dose of OMS721

Locations

24 sites in 12 countries. Site status is shown where the registry gives one.

  • Omeros Investigational Site

    Duarte, California

  • Omeros Investigational Site

    Rochester, Minnesota

  • Omeros Investigational Site

    New York, New York

  • Omeros Investigational Site

    Durham, North Carolina

  • Omeros Investigational Site

    Madison, Wisconsin

  • Omeros Investigational Site

    Brussels, Belgium

  • Omeros Investigational Site

    Leuven, Belgium

  • Omeros Investigational Site

    Liège, Belgium

  • Omeros Investigational Site

    Sofia, Bulgaria

  • Omeros Investigational Site

    Shatin, Hong Kong

  • Omeros Investigational Site

    Bergamo, Italy

  • Omeros Investigational Site

    Vilnius, Lithuania

  • Omeros Investigational Site

    Selangan, Malaysia

  • Omeros Investigational Site

    Christchurch, New Zealand

  • Omeros Investigational Site

    Katowice, Poland

  • Omeros Investigational Site

    Krakow, Poland

  • Omeros Investigational Site

    Lodz, Poland

  • Omeros Investigational Site

    Warsaw, Poland

  • Omeros Investigational Site

    Singapore, Singapore

  • Omeros Investigational Site

    Taichung, Taiwan

  • Omeros Investigational Site

    Taipei, Taiwan

  • Omeros Investigational Site

    Ban Pathumwan, Thailand

  • Omeros Investigational Site

    Bangkok, Thailand

  • Omeros Investigational Site

    Pathum Thani, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.